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Abstract
The purpose of this study was to develop a paradigm for quantitative molecular imaging of bone cell activity. We
hypothesized the feasibility of non-invasive imaging of the osteoblast enzyme alkaline phosphatase (ALP) using a small
imaging molecule in combination with
19Flourine magnetic resonance spectroscopic imaging (
19FMRSI). 6, 8-difluoro-4-
methylumbelliferyl phosphate (DiFMUP), a fluorinated ALP substrate that is activatable to a fluorescent hydrolysis product
was utilized as a prototype small imaging molecule. The molecular structure of DiFMUP includes two Fluorine atoms
adjacent to a phosphate group allowing it and its hydrolysis product to be distinguished using
19Fluorine magnetic
resonance spectroscopy (
19FMRS) and
19FMRSI. ALP-mediated hydrolysis of DiFMUP was tested on osteoblastic cells and
bone tissue, using serial measurements of fluorescence activity. Extracellular activation of DiFMUP on ALP-positive mouse
bone precursor cells was observed. Concurringly, DiFMUP was also activated on bone derived from rat tibia. Marked
inhibition of the cell and tissue activation of DiFMUP was detected after the addition of the ALP inhibitor levamisole.
19FMRS
and
19FMRSI were applied for the non-invasive measurement of DiFMUP hydrolysis.
19FMRS revealed a two-peak spectrum
representing DiFMUP with an associated chemical shift for the hydrolysis product. Activation of DiFMUP by ALP yielded a
characteristic pharmacokinetic profile, which was quantifiable using non-localized
19FMRS and enabled the development of
a pharmacokinetic model of ALP activity. Application of
19FMRSI facilitated anatomically accurate, non-invasive imaging of
ALP concentration and activity in rat bone. Thus,
19FMRSI represents a promising approach for the quantitative imaging of
bone cell activity during bone formation with potential for both preclinical and clinical applications.
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Introduction
Imaging is one of the most important diagnostic tools in the
clinical evaluation of patients with musculoskeletal conditions
[1,2]. The majority of current clinical musculoskeletal imaging
strategies are designed to detect abnormalities in bone morphology
as indicators of disease. For example, radiographs and computed
tomography measure tissue mineral density to visualize bone
anatomy. Similarly, current MR imaging techniques measure
proton (
1H, water, lipid) relaxation and density to visualize
musculoskeletal anatomy. Further, nuclear imaging agents,
including Na
18F for positron emission tomography and bisphos-
phonate tracers for bone scanning, principally target matrix/
mineral composition through physio-chemical uptake [3,4,5].
Lastly, more recent experimental approaches focused on fluores-
cent bisphosphonates as static probes for optical detection and
validated their potential as structural markers of bone turnover
[6,7,8].
While imaging approaches focused on measures of morphology
have allowed important insights into musculoskeletal pathology,
there has been a relative dearth in the development of functional
measures of bone biology [9]. Although limited in number,
methods for imaging bone biology have demonstrated great
potential. For example, one study used a commercially available
optical probe for detection of the osteoclast enzyme cathepsin K, a
marker of bone resorption [10]. While very promising, use of
fluorescence techniques is best suited for superficial applications
and does not offer anatomical localization of the light signal.
Further, it is unknown if this approach can be accurately
quantified in humans. In addition to imaging osteoclasts,
osteoblast activity during bone formation has been monitored in
transgenic mice expressing a bioluminescence imaging reporter
gene under the control of the osteocalcin promoter [11,12].
However, this strategy is limited to pre-clinical models due to the
requirement for transgenic animals. Collectively, existing ap-
proaches to imaging bone cell activity are considerably restricted
in scope and potential clinical application.
In this contribution, we present a clinically relevant paradigm
for the quantitative imaging of bone cell activity. The osteoblast
marker alkaline phosphatase (ALP) was visualized directly in bone
tissue with anatomical accuracy representing a first step towards
the development of imaging osteoblastic cell activity in living
subjects, including patients. The tissue non-specific ALP in bone is
an extracellular, membrane-bound enzyme that hydrolyzes
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While the in vivo substrates of bone ALP remain unclear, ALP is
considered an important regulator of mineralization, likely due to
its enzymatic degradation of the mineralization inhibitor pyro-
phosphate [14,15,16]. We have selected ALP for proof-of-
principle because it is a commonly used clinical marker of bone
formation [17]. The imaging paradigm herein is based on the
hypothesis that a fluorine-labeled ALP substrate and its hydrolysis
product demonstrate MR characteristics amenable to quantitation
and visualization using
19Fluorine MR spectroscopy (
19FMRS) and
spectroscopic imaging (
19FMRSI) (Fig. 1A). We demonstrate this
concept in a series of in vitro and in situ experiments.
6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) was
identified as a prototype small imaging molecule and substrate
for ALP. DiFMUP was detected and discerned from its hydrolysis
product by
19FMRS. Activation of DiFMUP by hydrolysis
occurred extracellularly on ALP-expressing osteoblasts. In addi-
tion, DiFMUP was activated on purified murine bone tissue in an
ALP-dependent fashion and this reaction was quantitatively
detected and visualized by
19FMRSI.
Materials and Methods
Materials
All chemicals, bovine kidney ALP, levamisole (L-tetramisole),
and the ALP histochemistry reagents (86-R) were procured from
Sigma (St. Louis, MI). The cell lines were obtained from ATCC
(Manassas, VA). DiFMUP was purchased from Molecular Probes/
Invitrogen (Carlsbad, CA).
Preparation of DiFMUP and Its Hydrolysis Product
The DiFMUP was dissolved in dimethylsulfoxide (DMSO) and
aliquots were stored at 220uC. The final DMSO concentration in
all assays was 5% v/v. DiFMUP was assayed in ALP buffer
containing 100 mM diethanolamine, pH 9.8, 50 mM MgCl2 or in
tissue culture medium at physiological pH. Alpha modifed Eagle’s
medium (a-MEM) supplemented with 10% fetal bovine serum,
2 mM glutamine, and penicillin (100 units/ml)/streptomycin
(100 mg/ml) was used because it also served as tissue culture
medium for the bone precursor cells studied in this report.
Activation of DiFMUP in the presence of 0.1 u purified bovine
kidney ALP was measured in a total volume of 500 ml for 1 hr at
37uC.
Fluorescence Measurements
Only the hydrolysis product of DiFMUP is fluorescent. We
selected a 358 nm excitation and 455 nm emission filter set to
measure DiFMUP hydrolysis using a Tecan Saphire (San Jose,
CA) plate reader with temperature control. We found it
convenient to assay samples in 24 well tissue culture plates (BD
Falcon, Bedford, MA). Acquisitions were performed in top read
mode with a bandwidth of 5 nm or 2.5 nm for 50 mMo r5m M
DiFMUP, respectively. An integration time of 40 ms with no lag
time was chosen. The gain was set manually to 100. The z-position
was calculated from well A1. Measurements were preceded by a
3 s shake followed by a 3 s rest period and included 100 flashes.
Measurement of DiFMUP Activation on Bone Precursor
Cells
As ALP-positive and negative mouse bone precursor cells, we
used 7F2 [18] and MC3T3-E1 #4 [19] cells, respectively. Cells
were grown as monolayers on tissue culture plastic in complete a-
MEMunder a humidified 5%carbon dioxideatmosphere. ForALP
histochemistry, cells were plated at 50% or grown to confluence.
They were fixed for 10 min in ice-cold phosphate-buffered saline
(PBS) containing 10% formalin and subsequently washed with PBS
and distilled water. Staining was performed for 20–30 min
according to the staining kit’s instructions. Then, cells were rinsed
in water, counterstained for 1 min in 1 ml Gill’s Hematoxylin,
washed, and air dried over night. To assay DiFMUP activation on
cells, we plated cells in triplicates in Falcon 24 well plates. On
average, 16 hrs before the assay 50,000 cells were seeded in a total
of 500 ml medium. The enzymatic reaction was initiated by
replacing 25 ml medium with 25 ml of 1 mM DiFMUP. Due to
an apparent sensitivity of 7F2 cells to DMSO, we maintained the
final DMSO concentration at 0.5% v/v.
Preparation of Bone Tissue
Ethics Statement: Animal studies were performed in accordance
with institutional guidelines and the approval of the IACUC at
Memorial Sloan-Kettering Cancer Center (Protocol #10-10-020).
Bone tissue was harvested post-mortem from 8–12 weeks old
Sprague-Dawley rats (Taconic, Hudson, NY). Both tibias were
surgically removed, carefully cleaned of soft tissue using a scalpel
and stored on ice prior to use. Specimens composed of metaphyseal
and diaphyseal bone were separated from bone marrow via at least
five grindings in a mortar. Each grinding was carried out in 6 ml
ice-cold PBS as 6–7 crushes. After each grinding, the bone marrow-
containing supernatant was removed and discarded. The resulting
highly purified bone chips had a white-translucent appearance.
Fluorescence measurements on bone were carried out in a total
volume of 500 ml. Either a single bone chip (3–5 mg) was assayed in
ALP buffer (the fluorescence read-out was normalized to the weight
of the bone chip) or 15 mg of bone were assessed in medium. Prior
to the measurement, samples were kept on ice. The enzymatic
reaction was initiated by replacing 25 ml of medium with the same
volume of 1 mM DiFMUP immediately before the fluorescence
measurement.
19FMRS on 30 mg of highly purified bone chips was
carried out in a total volume of 450 ml ALP-buffer with 20–25 mM
DiFMUP. For imaging, we prepared cortical diaphyseal bone from
intact tibia. The bone was split longitudinally into halves
approximately 5 mm in length, carefully cleaned from bone
marrow, and sandwiched in standard paper towel. Subsequently,
we placed the bone core-containing sandwich in a 500 ml cylinder
and carefully moisten it with approximately 250 mlo f5 m M
DiFMUP in ALP-buffer, added first to the core and then periphery
of the sandwich.
Magnetic Resonance Studies
MR studies were performed on a Bruker (Billerica, MA) Biospec
70/30 small animal imaging system operating at 7 T and
equipped with a 200 mT/m gradient coil insert. Experiments
were performed with the use of a temperature-control suscepti-
bility-matching water bath [20].
19Fluorine spectra and spectro-
scopic images were acquired using a custom-built, 1.0-cm inner
diameter, two-turn solenoidal coil optimized for transmission and
reception at 282 MHz. Spectral data was analyzed using the
jMRUI software package [21]. Quantitation of spins was achieved
through the use of the AMARES non-linear least squares
quantitation algorithm [22]. In accordance with the literature,
considerations relevant to data acquired using the external
reference technique were included in the analysis. Spin-lattice
relaxation times of DiFMUP with rat tibia chips were measured
for both the substrate and product and were used to correct for
partial saturation effects as described previously [23]. The spin
lattice relaxation times for the high and low frequency substrate
resonances were measured to be 2.1 s and 1.6 s respectively. The
spin lattice relaxation times for the high and low frequency
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22608Figure 1. Basic concept and specific detection of the ALP substrate DiFMUP by magnetic resonance spectroscopy. A: In this study,
imaging is based on the use of DiFMUP. This small imaging molecule prototype contains two MR-detectable fluorine atoms in direct vicinity to a
phosphate group. Prior to hydrolyzation by ALP, DiFMUP is expected to yield a spectrum characteristic of two discrete signals from the fluorine atoms
since the molecule is not symmetrical, and hence the fluorine atoms exist in distinct chemical environments. If ALP is present and catalyzes the
exchange of the phosphate to a hydroxy group, a significant change in the environment next to the fluorine atoms occurs and is expected to result in
a chemical shift variation of the fluorine signals that is detectable by
19FMRSI. An added advantage of DiFMUP is the fluorescent property of its
hydrolysis product; this allows for the convenient measurement of DiFMUP activation. This feature is not essential for the presented imaging
paradigm, however it is used to monitor ALP activity in several subsequent figures. B: The two-peak MR signal of DiFMUP at alkaline pH 9.8 relative to
a sodium fluoride (NaF) standard. C: An identical DiFMUP spectrum characteristic was observed under physiological pH 7.4 conditions. D and E: The
hydrolysis product of DiFMUP exhibits fluorescence properties, which allows one to record DiFMUP activation. Substantial activation of 50 mM (D) and
5 mM (E) DiFMUP in the presence of ALP was seen in both alkaline and physiological solutions. F and G represent MR spectra of DiFMUP and its
hydrolysis product, respectively. The discrete spectrum of the hydrolysis product is seen including resonances from non-equivalent fluorine atomsa t
217 ppm and 241 ppm relative to the sodium fluoride reference resonance.
doi:10.1371/journal.pone.0022608.g001
Imaging Bone Alkaline Phosphatase
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22608product resonances were measured to be 3.0 s and 2.3 s
respectively. Spectroscopic images and parametric maps were
generated using Paravision software (Bruker).
19Fluorine MRS
Samples for
19FMRS (n=5) were contained in 500 mL glass
vials (J. G. Finneran Associates, Vineland, NJ) and positioned
within the previously described two-turn solenoidal radiofrequency
coil. For purposes of quantitation a sealed glass microsphere
containing 18 mL of a 150 mM sodium fluoride (NaF) aqueous
solution doped with 15 mM Magnevist (Berlex Laboratories Inc.,
Montville, NJ) was positioned adjacent to the coil. The coil was
immersed in the water bath and positioned at the isocenter of the
magnet. Subsequent shimming optimized the magnetic field
homogeneity to a proton linewidth of approximately 30–60 Hz.
Optimized acquisition parameters included a 60u pulse-angle, a
1.7 s pulse repetition time, and a spectral width of 75 kHz in 2048
data points. Spectra were acquired as the average of 353
excitations enabling a temporal resolution of 10 min. per
spectrum. Serial spectra of DiFMUP and rat tibia were acquired
over a time period of 300 to 600 min following application of
DiFMUP. A single, fully-relaxed spectrum of the NaF reference
was acquired following the calibration of flip angles to ensure
accurate quantitation.
19Fluorine MRSI
Thesamples(n=3)forimagingwerepreparedforexperimentsas
described above. A chemical shift image sequence was used to
acquire a two-dimensional image with thirteen phase encode steps
at an in-plane resolution of 1.861.8 mm (FOV=24 mm). Phase
encode steps were acquired as the weighted average of 8500 FID
signals in 2048 data points with a spectral width of 50 kHz, 60u flip
angle and 1.7 s repetition time. The total imaging time was four
hours. Prior to MRS imaging, a proton image was acquired at
300 MHz for anatomic localization of the
19FMRSI spectra. A
rapid acquisition with relaxation enhancement (RARE) sequence
wasusedwith24 mmFOV,1926256matrixsize,6 signalaverages,
1000 ms repetition time and 102.5 ms echo time. A single, fully-
relaxed spectrum of the NaF reference was subsequently following
the calibration of flip angles to ensure accurate quantitation.
Kinetic Modeling of Serial
19FMRS Data
The ALP enzyme kinetics were modeled as a simple three-
compartment system. The three compartments correspond to: 1)
unbound DiFMUP substrate [S], 2) the enzyme-substrate complex
[ES] and 3) the DiFMUP hydrolysis product [P] concentrations. All
compartments were assumed to be well mixed. The DiFMUP
substrate was introduced as a bolus of known concentration and was
assumed to bind to the enzyme in a saturable process. The rate of
product formation was assumed to be unidirectional and proportional
to the enzyme-substrate complex concentration. The unbound
enzymeconcentration was taken to be the total (bound and unbound)
concentration of enzyme, parameterized by E0,m i n u s[ ES].
In mathematical terms, this system is described by the following
system of equations:
d S ½  ~{kon½S (E0{½ES )zkoff½ES 
d ES ½  ~kon½S (E0{½ES ){(koffzkcat)½ES 
d P ½  ~kcat½ES 
where the initial conditions for [S], [ES] and [P] are known (the
latter two being zero and the former being the bolus concentra-
tion) and with parameter kon in units of mM
21?min
21 and, koff and
kcat in units of min
21, and E0 a scalar parameter in units of mM.
Bound substrate [ES] is not seen by
19FMRS, thus the measured
substrate concentration directly reflects [S]. The model was used
to simultaneously fit the time-course of both [S] and [P],
minimizing the sum of the squares of the residuals while varying
the values of kon, kcat and [E] using a nonlinear search procedure.
The system of differential equations was solved and the fitting
procedure was performed, using code written in Matlab. Four
parameter values, kon, koff, kcat and E0, were independently
determined for each of the three serial time-course experiments.
All measured data points were weighted equally during the fitting
process.
Modeling of
19FMRSI Data
The model of the FMRSI data made use of the same system of
equations applied to serial
19FMRS datasets except in this case the
parameter values for kon, koff and kcat were fixed at the means of the
values determined in the serial experiments. Only E0 was allowed
to vary for each image pixel along with a new parameter w, which
accounted for the partial volume averaging of a given pixel with
air or the walls of the vessel. Values for w were bound to a
maximum value of one and for each pixel a single value of w was
used to scale both the modeled DiFMUP substrate and hydrolysis
product concentrations. The mean values of the modeled substrate
and product time-courses over the period of the
19FMRSI
measurement (60 to 300 min post injection) were fitted to
measured concentrations, minimizing the sum of the squared
errors while varying E0 for each pixel.
Results
MRS Detection of Hydrolysis of DiFMUP In Vitro
To assess the feasibility of DiFMUP detection by
19FMRS, the
compound was prepared in alkaline (ALP-buffer) or physiological
(tissue culture medium) solution. DiFMUP was detected as a two
peak spectrum representing non-equivalent fluorine atoms at
210 ppm and 227 ppm relative to the sodium fluoride reference
resonance (Fig. 1B). No change in the DiFMUP spectrum was
noted between ALP-buffer and medium (Fig. 1B and C). Next,
DiFMUP was activated via hydrolysis in the presence of purified
ALP. Utilizing the fluorescent properties of the DiFMUP
hydrolysis product, a strong increase (100-fold) in fluorescence
was registered following a one hour incubation (Fig. 1D). A robust
increase (20-fold) in fluorescence was also observed at millimolar
concentrations of DiFMUP; however, fluorescence quenching was
noted due to a high fluorophore concentration (Fig. 1E).
19FMRS
was subsequently applied to measure the activation of DiFMUP by
purified ALP. As hypothesized, a characteristic four peak spectrum
was observed with a pronounced chemical shift of two additional
resonances relative to those seen for DiFMUP corresponding to
the non-equivalent fluorine atoms of the hydrolysis product.
(Fig. 1F and G). Thus,
19FMRS was able to discern DiFMUP and
its hydrolysis product.
Extracellular Hydrolysis of DiFMUP in ALP Positive Bone
Cells
To test the activation of DiFMUP by ALP-expressing
osteoblastic bone cells, we compared ALP-positive 7F2 cells
(Fig. 2A, panel 1 and 2) to MC3T3-E1#4 cells which were
negative for ALP (Fig. 2A, panel 3 and 4). Activation of DiFMUP
was restricted to the ALP-expressing 7F2 cells (Fig. 2B) as the
fluorescence registered from the MC3T3-E1#4 cells remained at
background levels (Fig. 2B). Next, we analyzed the distribution of
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product was recovered from the medium as compared to the cell
monolayer (Fig. 2C). Together, these data demonstrate the
extracellular hydrolysis of DiFMUP by ALP-positive osteoblastic
bone cells.
Efficient ALP-dependent Activation of DiFMUP in Bone
Tissue
The extracellular activation of DiFMUP by ALP-positive bone
cells in tissue culture suggested an ALP-dependent hydrolysis
within bone tissue. To investigate this possibility, rat tibia was
prepared. Highly purified bone tissue maintained in medium was
found to activate DiFMUP (Fig. 2D). The course of DiFMUP
activation was comparable to the one observed in the presence of
ALP-positive 7F2 cells (Fig. 2B). As shown in Fig. 2D, the
hydrolysis was significantly reduced in the presence of 2 mM
levamisole, a known ALP inhibitor. A comparable inhibition was
seen with 10 mM EDTA (not shown). The accelerated enzymatic
reaction in ALP-buffer enabled measurements on single pure bone
chips (Fig. 2E). In comparison to the measurement in medium, a
more pronounced inhibition by levamisole was seen and resulted
in an approximately 80% reduction in fluorescence after 60 min
(Fig. 2E).
Quantitative Imaging of Alkaline Phosphatase in Bone
Tissue
To achieve
19FMRSI of ALP activity in bone tissue, we first
performed serial
19FMRS on highly purified rat cortical bone
chips in solution. These serial
19FMRS time series measurements
delineated the kinetics of ALP-mediated activation of substrate to
its hydrolysis product and demonstrated that
19FMRS is an
effective method for detecting ALP-mediated activation of
DiFMUP to its hydrolysis product. (Fig. 3A). Absolute metabolite
concentrations derived from these
19FMRS time series measure-
ments were fit to a pharmacokinetic model describing the kinetics
of bone alkaline phosphatase activity. The result of the fitting
procedure for a representative serial experiment is shown in
(Fig. 3B). The mean and coefficient of variation of each parameter
over the three experiments was calculated to be: kon 1.726
10
24 mM
21?min
21 (622%), koff 2.03610
23 min
21 (661%), kcat
5.27610
23 min
21 (639%), and E0 33.6 mM (631%).
This relationship allowed the application of the pharmacoki-
netic model to achieve quantitative images of bone alkaline
phosphatase activity in living bone tissue. We prepared a sample in
which a core of bone slivers was wrapped with paper towel soaked
in 5 mM DiFMUP. A high resolution RARE MR image was
initially obtained for the purpose of voxel prescription and co-
Figure 2. ALP-dependent DiFMUP activation on the surface of ALP-positive osteoblastic bone cells and in the presence of rat tibial
bone. A: Histochemistry detected ALP expression as violet-red staining on 7F2 cells as shown in low and high magnification images 1 and 2,
respectively. In contrast, no ALP expression was detectable on the MC3T3-E1#4 cells shown also in low (3) and high magnification (4). B: Activation
(hydrolysis) of DiFMUP occurred on 7F2 cells (closed squares), but not on ALP-negative MC3T3-E1#4 cells (open triangles). No-cell background (Bkg)
measurements are also presented (open circles). C: Following the separation of cells (CE) and medium (M) and a single wash step (W), the vast
majority of the hydrolysis product was found in the medium. Mean values and standard deviations are shown (n=3). D: DiFMUP in physiological
solution was activated in a time-dependent fashion in the presence of highly purified rat tibia bone (closed squares). Addition of the ALP inhibitor
levamisole reduced DiFMUP activation (open squares). E: DiFMUP in alkaline solution was activated by a single highly purified tibia bone chip (closed
squares). Presence of levamisole significantly suppressed the activation (open squares). Mean values and standard deviations are shown (n=3).
doi:10.1371/journal.pone.0022608.g002
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19FMRS images (n=3)
were acquired demonstrating the concentrations of DiFMUP
substrate and hydrolysis product in a 0.1 cm
3 volume with an in-
plane resolution of 1.861.8 mm (Fig. 4B and C, respectively). We
observed that the DiFMUP was mostly present in the periphery of
the sample (Fig. 4B), while the hydrolysis product localized to the
region of ALP enzymatic activity within the bone core (Fig. 4C).
The measured concentrations of DiFMUP and its hydrolysis
product enabled the generation of parametric maps of regional
ALP concentration and activity (Fig. 4D). Together, these data
demonstrate imaging of osteogenic bone cell activity. In allowing
the quantitative imaging of regional ALP enzymatic activity this
approach provides an ideal platform for the further development
of quantitative imaging of bone cell activity in living subjects.
Figure 3. Pharmacokinetics of ALP-dependent DiFMUP activation in the presence of rat tibial bone. A: Representative serial
19FMR
spectra of DiFMUP and its hydrolysis product in the presence of rat bone. Spectral acquisition was initiated 6 minutes after addition of DiFMUP (20–
25 mM range) to highly purified rat bone chips and serial spectra were acquired with 10 min temporal resolution. Peak assignments are as described
for previously demonstrated spectra including (1) sodium fluoride, (2,4) DiFMUP and (3,5) DiFMUP hydrolysis product. B: The measured and modeled
time course kinetics of unbound DiFMUP (x, —) and its hydrolysis product (x, —) for the
19FMR spectra seen in Fig. 3A. The modeled ALP bound
DiFMUP (—) is also shown for comparison.
doi:10.1371/journal.pone.0022608.g003
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Quantitative, diagnostic imaging of the biology which underlies
post-natal bone remodeling and repair as well as metabolic bone
diseases and skeletal malignancies, has been postulated as
important for the development of next-generation clinical
musculoskeletal imaging [9,24,25,26,27,28,29]. Toward this goal,
we demonstrate proof-of-principle quantitative imaging of bone
cell activity in explanted living bone. The activity of the bone cell
marker ALP was exploited to enable the direct visualization of
bone cells ‘‘at work’’, i.e. osteoblasts forming bone. Imaging
cellular bone markers is a logical translation from their routine use
in clinical chemistry where they have been proven to be valuable
indicators of bone biology [30]. In contrast to clinical chemistry,
however, non-invasive imaging offers striking advantages including
the non-destructive measurement of biological activity in vivo and
in real-time allowing serial measurements within bone anatomy.
The importance of imaging bone cell activity is underscored by the
finding that controlled changes in the activity of bone cells, such as
osteoblasts or osteoclasts, precede changes in bone mineral or
matrix composition, thus potentially offering earlier and more
precise diagnostic imaging in future clinical applications [9,31].
We describe a paradigm for imaging osteoblast activity that applies
19FMRSI in combination with the small imaging molecule
prototype DiFMUP, an ALP substrate.
The small imaging molecule
Small molecule substrates provide an excellent tool for the
detection of enzymes such as ALP in basic research and clinical
chemistry. A classic example is the frequently used 5-bromo-4-
chloro-3-indolyl-phosphate which hydrolyzes into a reactive
intermediate that can further react into a dye. Among the large
selection of commercially available ALP substrates are also
molecules, including adamantly 1,2 dioxetane phosphate deriva-
tives, which disintegrate upon hydrolysis with the concomitant
release of chemiluminescent light. In contrast to these two
substrate types, other small molecule substrates maintain their
integrity forming hydrolysis products that emit visible or
fluorescent light. For example, para-nitrophenylphosphate pro-
duces a compound of yellow color while latent precursor substrates
such as fluorescein diphosphate or 4-methylumbelliferyl phosphate
derivatives, including DiFMUP, form fluorophores. The potential
for high-throughput in combination with the high sensitivity
offered by probes with optical properties have led to their
emergence for in vitro applications; however, their suitability for in
vivo imaging in mineralized tissues is limited mainly because of the
restricted depth of light penetration. Thus, we have explored
molecular detection traits other than optical properties using an
established small molecule substrate. DiFMUP was selected as a
prototype small imaging molecule because it harbors two MR-
Figure 4. Non-invasive imaging of ALP activity in rat tibia cortical bone. A: RARE
1H images of the bone sample anatomy including the rat
tibia cortical bone core within the glass vial. B and C:
19FMRSI-derived parametric maps of regional DiFMUP and hydrolysis product concentrations
overlaid onto RARE
1H images of the bone sample (B and C, respectively). D:
19FMRSI-derived parametric maps of regional ALP concentration and
activity overlaid onto RARE
1H images of the bone sample.
doi:10.1371/journal.pone.0022608.g004
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19F atoms in direct vicinity to an ALP cleavage site. The
advantages of DiFMUP include its availability to the research
community and the fluorescence properties of its hydrolysis
product, which make it amenable to in vitro characterization
assays. Importantly, the development of small imaging molecules
as substrates for the non-invasive measurement of ALP activity is
not restricted to DiFMUP. The essential motif within the
DiFMUP molecule conferring the potential for non-invasive
MRSI of bone cell activity is limited to the inclusion of a naturally
abundant
19Flourine atom and an ALP-cleavage site. As this motif
comprises a relatively small number of structural elements, it can
potentially be integrated into a large number of compounds in
order to generate rationally designed small imaging molecules for
bone diagnostics. The disadvantages of the prototype small
imaging molecule DiFMUP include a limited specificity and a
lack of data supporting in vivo use. Given the similarity among the
active sites among several tissue non-specific ALP isotypes it may
be difficult to achieve high selectivity for ALP in bone. This
limitation may be obviated by a local delivery strategy which may
include local administration of the small imaging molecule, the use
of a bone cell-activated precursor, or the application of bone
seeking carriers for targeted delivery.
Imaging
Magnetic resonance imaging continues to play an increasing
role in the clinical diagnosis of musculoskeletal disease. In
addition, many institutions are engaged in MR research using
dedicated scanners that can accommodate both mice and rats
making MRSI an attractive translational imaging method. In
comparison to optical imaging of bone [6,7,8,10,11,12], MR
technology provides unrestricted deep-tissue imaging, unmatched
anatomical detail, and absolute quantitation. The limitations of
MRI include relatively high costs and labor demand per scan as
well as field strength-dependent sensitivity. In previous pre-clinical
studies in mice, we were able to detect concentrations as low as
1 mM of fluorinated drugs in tumor tissue at 7 T [32]. The
increased sensitivity afforded by the use of higher magnetic field
strengths in clinical imaging offers the potential for the increased
application of heteronuclear MRSI. The described approach
offers the potential to combine functional measures of bone
biology using MRSI with the wealth of knowledge that has been
accrued using
1H MR imaging of musculoskeletal anatomy. To
the best of our knowledge,
19Fluorine-based MRSI has not
previously been applied for the imaging of enzymatic activity in
skeletal tissue. The versatility of this paradigm suggests that it can
be adapted for additional applications in musculoskeletal biology
including activities of enzymes other than ALP, such as osteoclast-
associated proteinase activity.
The described imaging strategy may be implemented pre-
clinically or clinically on existing MR scanners; however, future
applications combining the described MR-based imaging with
established nuclear medicine techniques hold the potential to
augment the diagnostic information provided by either approach
when used as a single modality. For example, while Na
18F positron
emission tomography (PET) permits the sensitive detection of
abnormalities in the bone mineral/matrix composition, the
predictive diagnostic value of
18Fluorine imaging is limited by
the inability to distinguish whether areas of mineral/matrix
alteration are associated with further bone resorption, new bone
formation, or solely represent areas of devitalized bone/matrix.
The small imaging molecule-based MRSI reported here will be
able to add a layer of biological information to the
18Fluorine
imaging because it can detect and measure bone formation in
areas of altered bone mineral. Thus, the osteogenic potential of
such areas can be determined, likely resulting in imaging with
increased diagnostic precision and prognostic capability. Another
potential application of a combination of MRSI of osteoblast
activity and nuclear imaging relates to the diagnosis of primary
and secondary skeletal cancers. In these diseases, PET would
deliver metabolic tumor imaging, while the small imaging
molecule-based MRSI would image the bony environment of
the tumor, thereby examining the nature of the cancer-bone
interaction. We anticipate that the physical principle that governs
the presented imaging is fully compatible with all standard nuclear
imaging for musculoskeletal disease including single photon and
positron emission techniques. Integration of the latter with MRSI
is attractive because both MRSI and PET allow tomographic
imaging and
1H MRI, which is an integral part of MRSI, can
provide high-resolution imaging of the underlying anatomy for
both the MRS and PET. The feasibility of MR/PET integrated
dual modality imaging is not only supported by recent pre-clinical
research [33] but underscored by the development and clinical
implementation of MRI/PET scanners [34,35]. Collectively,
potential applications of combined MRSI of osteoblast activity
and Na
18Fo r
18FDG PET include the evaluation metabolic bone
disease, infection, as well as primary and secondary skeletal
cancers.
Conclusions
Taken together, we have presented the first example of direct
molecular imaging of cell activity associated with bone formation.
We have demonstrated the feasibility of anatomically accurate
visualization of ALP activity in bone tissue. The MR/small
imaging molecule-based paradigm has implications for both
preclinical and clinical imaging. On-going preclinical studies are
focusing on the added benefits this approach may offer in models
of musculoskeletal disease. These early studies will lay the
foundation for the development of this clinically relevant approach
toward in vivo preclinical studies and suggest the potential for
applications in patients.
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